The new anti-cancer drug BPB-101 bispecific antibody injection has successfully entered the phase 2 clinical stage, and the new drug is the main research of the Cancer Center of Sun Yat-sen University. The new drug can help patients with lung cancer, liver cancer, bladder cancer, uterine cancer, ovarian cancer, breast cancer, tongue cancer, laryngeal cancer, stomach cancer and other cancers
BPB-101 bispecific antibody injection is a brand-new potential first-in-class (FIC) macromolecule new drug with completely independent intellectual property rights, which is a humanized antibody with a three-function bispecific IgG1 subtype. Now the list of **tertiary hospitals** is announced to confirm the authenticity of the new drug**:
Preclinical studies have shown that BPB-101 can specifically target the GARP-TGF-1 complex, mature TGF- and PD-L12, thereby relieving the dual immunosuppression of the TGF- signaling axis and PD-1 PD-L1 signaling axis in the tumor microenvironment, restoring and enhancing the killing effect function of immune cells on tumors, thereby inhibiting tumor growth and) survival.
I hope that patients in the clinic will nod their heads and say hello, and I will try my best to help patients enter the clinic and continue their lives through the clinic!You can**take a look at the anti-cancer article, and save someone's life casually, thank you!